Infant botulism results from the absorption of heat-labile neurotoxin produced in situ by ingested Clostridium botulinum. Honey and environmental exposure are the main sources of acquisition of the organism. Clinical manifestations are owing to progressive neuromuscular blockade, initially of muscles innervated by cranial nerves and later of the trunk, extremities and diaphragm. Presynaptic autonomic nerves are also affected. The diagnosis is made on clinical grounds and is confirmed by recovery of the organism or by detection of toxin in the stool. Management includes meticulous supportive intensive care that may include mechanical ventilation and administration of human botulinum immunoglobulin in severe cases.
Infant botulism (IB) results from absorption of heat-labile neurotoxin produced in situ by Clostridium botulinum that can colonize the intestines of infants younger than 1 year. 1 It is an age-limited neuromuscular disease that is distinct from classic botulism in that the toxin is elaborated by the organism in the infant's intestinal lumen and is then absorbed. Microbiology C. botulinum is a Gram-positive spore-forming obligate anaerobe that is present in the soil worldwide, and may spread by dust. It is composed of four groups of clostridia (groups I to IV), linked by their ability to produce potent neurotoxins that have identical pharmacologic modes of action. Botulinal toxin is the most potent neurotoxin known. 2 The toxin does not appear to cross the blood-brain barrier, and it exerts its toxicity by affecting the transmission at all peripheral cholinergic junctions. It interferes with the normal release of acetylcholine from nerve terminals in response to depolarization. 3 The toxin binds irreversibly, and recovery of function depends on ultraterminal sprouting of the nerve to form new motor end plates. Nerve terminal sprouts increases in number, length and complexity even after the functional recovery of neuromuscular transmission.
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Epidemiology IB is a restricted age-range disease. Ninety-five percent of all recognized cases have occurred in patients between 6 weeks and 6 months of age. The disease affects equally all major racial and ethnic groups and both sexes. More than 1500 cases of IB have been confirmed in the USA since it was recognized in 1976. Since that time, it has been the most frequent form of botulism, accounting for B60% of all cases, with a median of 71 cases annually. [6] [7] [8] IB is the most common form of botulism, with about 80 to 100 cases reported annually in the USA. 9 Almost all cases of IB are caused by proteolytic C. botulinum group I strains that produce either type A or B (or Bf) neurotoxin. However, type E and F neurotoxins have been recovered from infants with botulism due to Clostridium butyricum 8, 10 and Clostridium barati, [9] [10] [11] [12] respectively. IB has been reported from all inhabited continents except Africa. In the USA, differences in the regional soil distribution of C. botulinum exist. C. botulinum spores that produce toxin B are mainly found east of the Mississippi river, 13 whereas neurotoxin type A spores predominate in the soils west of it. A similar distribution was found in the case of IB. Geographic clustering of the cases had also been noted. [14] [15] [16] Predisposing conditions and pathophysiology IB results from the ingestion of C. botulinum spores. Even though honey is a known source, in about 85% of patients the source is unknown. IB cases occur from 6 days to 12 months of age and not later. Information derived from a mouse model and clinical cases suggest that transient absence of competitive microbial intestinal flora and/or alteration in motility or pH enables outgrowth of vegetative forms from ingested spores. Exclusively breast-fed infants during weaning have changes in intestinal flora, which may increase the risk for IB.
Replicating C. botulinum, and occasionally Clostridium baratii and Clostridium butyricum, produce distinctive botulinal neurotoxins (types A to G) of high potency. After systemic absorption, toxin binds to receptors on presynaptic nerve endings of cranial and peripheral nerves and blocks acetylcholine release. 17 Excretion of the organism has persisted for as long as 158 days after the onset of constipation, well after clinical recovery had occurred. The syndrome has occurred in both breast-fed and bottle-fed infants, and the role of type of feeding is yet unsettled. 18 Colonization is believed to occur because normal bowel flora that could compete with C. botulinum has not been fully established.
Risk factors for IB are multifactorial and include breast feeding, and the introduction of first formula feeding, consumption of honey and residence in a region of high spore density and soil disruption. 15 Constipation appears to be a risk factor but also is an early manifestation of intoxication. 8 Breast feeding is a risk factor for IB in all studies. [18] [19] [20] [21] [22] [23] [24] These infants may have a slower progression of illness/symptoms so that there may be a delay in hospitalization owing to later identification of illness. However, among hospitalized infants, the formula-fed reported from California 18 had a mean age of onset (7.6±8.4 weeks) that was significantly less than that of their breast-fed counterparts (13.7±8.4 weeks). The younger age at onset for formula-fed infants may reflect their earlier availability of suitable ecological niches for C. botulinum in the intestinal flora of the formula-fed infants, 13, 21 as well as the lack of immune factors that are contained in human milk. Long et al., 13 who reported 44 patients with IB from southeastern Pennsylvania, found that the majority of their patients had just formula feedings or other food introduced within 4 weeks of onset. The resident gut microflora is capable of blocking the outgrowth and multiplication of C. botulinum spores. The difference in the fecal flora of breast-and formula-fed infants may account for the increased earlier susceptibility of formula-fed infants to IB. Infants fed human milk have more acidic feces (pH 5.1 to 5.4) that contain a large number of Bifidobacterium (B10 10 /g). Clostridium (as spores) are virtually absent. 24 In contrast, formula-fed infants have less acidic feces (pH 5.4-8.0), which also contain Clostridium spp as well as other anaerobes and facultative bacteria. 19 The difference in pH may be important, because multiplication of C. botulinum and toxin production declines with reduced pH.
Preformed toxin has not been identified in food ingested by the infants, but the organism has been identified in honey, vacuum cleaner dust and soil. C. botulinum organisms, but no preformed toxin, were identified in six different honey specimens fed to three California patients with IB, as well as from 10% (9/90) of honey specimens studied. 25 By food exposure history, honey was significantly associated with type B IB. In California, 20% (56 of 272) of hospitalized patients had been fed honey before onset of constipation, 26 in Utah 83% (10 of 12) 21 and in southeastern Pennsylvania 14% (6 of 44). 13 Worldwide, honey exposure occurred in 35% (28/75) of hospitalized cases. Of all food items tested, only honey contained C. botulinum organisms.
The organism and its toxin have rarely been identified in the feces of normal infants. 27 C. botulinum was isolated from the stools of three normal control infants and nine control infants who had neurologic diseases that clearly were not IB. 21 These infants were termed 'asymptomatic carriers' of the organism. The occurrence of the asymptomatic carrier state suggests that a diagnosis of IB cannot be made on the basis of culture results alone, but must rest in historical and physical confirmation of progressive bulbar and extremity weakness with ultimate complete resolution of symptoms and findings over a period of several months.
A distinct seasonal incidence of IB was observed in one study carried out in Utah. 21 All the cases were reported between March and October with no reported cases during the winter months. The seasonal incidence suggests that the temperature and moisture factors that favor proliferation of C. botulinum in the soil could be of major importance. No apparent temporal relationship existed between cases and season, temperature or rainfall in the 44 cases reported from southeastern Pennsylvania. 13 A common set of environmental features was found to be characteristic of the home environment of children with IB and asymptomatic carriers and includes nearby constructional or agricultural soil disruption, dusty and windy conditions, a high water table and alkaline soil conditions. 21 These conditions of high soil water and alkaline content, which are favorable for the growth of C. botulinum, 11 were found near the homes of all affected infants. The dissemination of the organism appeared to be further enhanced by construction and agricultural soil disruption as well as windy conditions near the homes of most affected infants and asymptomatic carriers.
About half of patients' fathers in the cases reported in Pennsylvania 20 had occupations that brought them into daily contact with soil. Spores were recovered from yard soil, window sills, cribs or fathers' shoes in seven of nine instances in which environmental sampling was carried out. About 43 of the 44 cases occurred in infants who resided around the city of Philadelphia, and only one infant was from the city. A possible explanation for this discrepancy is the disruption of soil in the city, or little occupational contact with soil in the city compared to the surrounding areas.
The ubiquitous distribution of C. botulinum spores 5 in nature allows for their ingestion by many infants. The fact that ingested spores can germinate in some, but not all, infants generally between 1 and 6 months old indicates that host factors unique to this age play a central role in pathogenesis. Host factors are of great importance, a point emphasized by the broad spectrum in the severity of disease.
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Clinical manifestation
The onset ranges from insidious to abrupt. The syndrome is characterized by a history of constipation (defined as 3 or more days without bowel movement) followed by a subacute progression of bulbar and extremity weakness (within 4 to 5 days) manifest in inability to suck and swallow, weakened voice, ptosis, hypotonia, which may progress to generalized flaccidity and respiratory compromise. There is, however, a broad clinical spectrum of IB. The mild end of the spectrum appears to be represented by infants who never require hospitalization but who have feeding difficulties, mild hypotonia and floppy neck, and failure to thrive, whereas the severe end of the spectrum may be characterized by a presentation resembling sudden infant death syndrome (SIDS), 28 and these patients require hospitalization for treatment of their respiratory and feeding difficulties.
The main clinical feature of the syndrome is constipation, which occurs in about 95% of patients. 16, 29 Botulism is expressed clinically as a symmetric, descending paralysis. Early in the progression, weakness and hypotonia is typical, and the first sign of illness is in the cranial nerves, in the form of bulbar palsies. Less vigorous crying or sucking or subdued facial expression generally is the first sign. Weakness progresses in a symmetric descending fashion over hours to a few days, from muscle innervated by cranial nerves to those of trunk and limbs. A marked dichotomy between the normal physical and abnormal neurological findings usually occurs.
The time between the onset of constipation and onset of weakness ranges from 0 to 24 days (mean 11 days). Progression is more severe in infants younger than 2 months. 14, 30 Obstructive apnea due to the hypotonia leading to collapse of the hypopharynx support can occur rapidly in this age group. The infants may also manifest tachycardia, difficulty in sucking and swallowing, listlessness, weakening, hypotonia, general muscular weakness with a loss of head control and pooling of oral secretions. These babies appear 'floppy,' and may manifest various neurologic signs such as ptosis, ophthalmoplegia, sluggish reaction of the pupils, dysphagia, weak gag reflex and poor anal sphincter tone. 31, 32 In seriously ill babies, respiratory arrest may occur.
The nadir of paresis and paralysis generally occur within 1 or 2 weeks. The resolution of disease signs and symptoms occurs in the inverse order of presentation, with autonomic finding the last to regress. Once strength and tone begin to return, the improvement continues over the following weeks in the absence of complications. It is important to minimize interventions that increase complications. 33 It is important to remember that at this stage of the disease, return of peripheral motor activity does not signify complete reversed cholinergic synapse. The infant is highly susceptible to events that will additionally stress or impair neuromuscular transmission. Such events may lead to sudden respiratory arrest or gradual respiratory failure. Two specific factors have been associated with respiratory decompensation in IB: administration of aminoglycoside antibiotics and neck flexion during positioning for lumbar puncture or computerized axial tomography (CAT) scan. 34, 35 Aminoglycoside antibiotics decrease acetylcholine release from nerve terminals innervating the diaphragm, leading to diaphragmatic weakness and respiratory failure.
Differential diagnosis
The most frequent admission diagnoses of infants later found to have IB include sepsis, viral syndrome, dehydration, diphtheria, cerebrovascular accident, hypothyroidism, hypermagnesemia, failure to thrive, Lambert-Eaton Myasthenic syndrome, myasthenia gravis, poliomyelitis, Guillain-Barré syndrome, encephalitis and meningitis. Several hereditary endocrine or metabolic disorders considered are amino-acid metabolism disorder, Werdnig-Hoffmann disease and drug or toxin ingestion. Diagnoses less frequently considered include subdural effusion, infectious mononucleosis, brain stem encephalitis, animal bite or sting, organophosphate poisoning, carbon monoxide intoxication, methemoglobinemia, myoglobinuria, glycogen or lipid storage diseases, congenital muscular dystrophy, myotonic dystrophy, congenital myopathy, atonic cerebral palsy and diffuse cerebral degenerative disease.
Even though sepsis may be considered in the differential diagnosis, infants with botulism are afebrile, alert, have robust skin color, but are hypotonic or paralyzed.
Diagnosis
The diagnosis is made on clinical grounds and is confirmed by identification of the neurotoxin in the stool, when necessary by sterile enema.
The diagnosis of IB is established unequivocally when C. botulinum organisms are identified in a patient's feces, as C. botulinum is not part of the normal resident intestinal microflora of infants or adults. [36] [37] [38] The mouse neutralization assay is used to test for the presence of toxin in feces or the serum. Therefore, serum and fecal specimens should be collected as soon as the diagnosis of botulism is suspected. It is sometimes possible to identify small amounts of the toxin in serum if the specimen is collected early in the illness. 39 An enzyme-linked immunosorbent assay (ELISA) has recently been developed for rapid detection of toxins A and B in IB. 40 This test allows detection within 24 h as compared to 4 days that are required for the mouse assay. The toxin can be identified in the stool of affected infants as long as 4 months after onset of symptoms, well into recovery.
Other specimens that are important for the epidemiologic investigation should also be collected, including suspected food, Infant botulism I Brook drug and environmental samples. All specimens should be transported in insulated containers with cold packs and remain at temperatures of at least 41C. Specimens for botulism investigation can be submitted to state health department or the Centers for Disease Control in Atlanta, Georgia, USA.
Routine laboratory tests such as blood chemistry, blood count and urinalysis generally are normal. Mild dehydration and fat mobilization because of decreased oral intake may be present at admission. A few cases have shown slight elevation in the cerebrospinal fluid protein because of dehydration. 32 The only procedure that consistently corroborated the clinical diagnosis of IB was electromyography (EMG). The EMG shows a characteristic pattern of (1) brief, small-amplitude, abundant, motor-unit action potential (BSAP), 36 (2) enhancement of compound action potential in response to rapid repetitive nerve stimulation, (3) normal nerve conduction velocity and (4) no response to edrophonium chloride or neostigmine injection. 41 As clinical recovery occurs, normal motor-unit activity reappears.
EMG can provide rapid bedside substantiation of the clinical diagnosis of IB. If the BSAP pattern is present, 36, 42 then many of the other diagnostic tests and procedures to which patients are subjected may be deferred whereas laboratory examination of fecal specimens for C. botulinum toxin and organisms proceeds.
Unfortunately, EMG is not in itself diagnostic. The BSAP pattern may be seen in diseases of the terminal motor nerve axons, the neuromuscular junction or of muscle itself. [43] [44] [45] Furthermore, failure to detect the BSAP pattern does not exclude the diagnosis of IB. The EMG pattern of post-tetanic facilitation, observed often in food-borne botulism, may be found in a variety of other disorders besides botulism. [43] [44] [45] A controversy exists regarding the sensitivity and specificity of EMG depending on the point in course of the illness and the timing and amount of nerve stimulation. 37, 45 Because of the unique clinical findings and the availability of toxin assay, the painful EMG testing is not usually performed.
Management
Children with IB presenting with mild symptoms require minimal care and can be managed as outpatients if careful follow-up is arranged. Infants with severe IB constitute a select group who are at risk for respiratory failure. These infants can be identified by their progressive sequential loss of neurological functions.
Seriously ill patients require hospitalization for up to 2 months. Careful maintenance of adequate ventilation and caloric intake is of particular importance. The need for respiratory assistance, if any, generally occurs during the first week of hospitalization. Parenteral antibiotic therapy in an attempt to eradicate C. botulinum toxin and organisms from the intestinal tract usually is unsuccessful and should be reserved for cases with proved or suspected sepsis caused by other organisms.
When penicillin or its derivatives have been used, neither oral nor parenteral administration succeeded in producing discernible clinical benefit or in eradicating either C. botulinum organisms or botulinus toxin from the intestine. 13, 36 Antibiotics are not recommended for IB and will not effect the course of illness or recovery.
Effective antibiotics may increase the pool of toxin in the bowel available for absorption as it is liberated following bacterial cell death. Another argument against the use of antimicrobial agents is that these agents may alter the intestinal microecology in an unpredictable manner and might actually permit intestinal overgrowth by C. botulinum by eliminating the normal flora.
Aminoglycosides may potentiate neuromuscular weakness caused by C. botulinum toxin. It is, therefore, suggested that these antibiotics should be used with caution in suspected cases of IB. In large doses, gentamicin, along with other aminoglycosides, has been demonstrated to produce a nondepolarizing type of neuromuscular block. 34 As C. botulinum toxin is known to block the release of acetylcholine from cholinergic nerve endings, 2,3 gentamicin may potentiate sublethal concentrations of the toxin and result in complete neuromuscular blockade and resultant paralysis. L'Hommedieu et al. 34 provide clinical data and Santos et al. 46 provide animal data to support this hypothesis.
The present treatment of IB consists of meticulous supportive care, with particular attention to nutrition, pulmonary hygiene and good nursing care. Immediate access to an intensive care unit and to mechanical ventilation is especially important because aspiration or apnea may occur. Associated conditions such as dehydration, aspiration pneumonia and anemia should also be treated. The respiratory aspects of the patient should be addressed by performing frequent suctioning and stimulation, mechanical ventilation, monitoring of oxygen saturation and administration of oxygen. When IB is suspected, monitoring for both apnea and bradycardia should be instituted; endotrachael intubation or tracheostomy may be required in some cases. Monitoring should continue until sufficient breathing, coughing and swallowing ability have returned so that apnea and aspiration are unlikely to occur. The need for nutritional support can require gavage feeding, intravenous glucose and electrolytes and sometimes hyperalimentation. Because bladder atony is often present, the bladder should be emptied frequently by credé method. Tube feeding may stimulate peristalsis and has been used successfully in most patients. Patients should not be fed by mouth until they are able to gag and swallow. The patients should receive mother's-milk, if available. Otherwise, formula without added iron is the next choice. Intravenous feeding has been used as a last resort. To reduce the quantity of C. botulinum organisms and toxin in the intestine, cathartic agents or bulk laxatives may be judiciously administered if adynamic ileus is absent, but rarely have these proved efficacious.
As patients excrete C. botulinum toxin and organisms in their feces for weeks to months after they have returned home, it is important to adhere to careful hand washing and diaper disposal. Enemas and purgatives, clostridiocidal antibiotics, cholinomimetic drugs (i.e., guanidine, 4-aminopyridine) 47 and the equine botulinum antitoxin had no beneficial effects.
The IV botulinum immune globulin (BIG) trials in California that were completed in early 1997 demonstrated the safety and efficacy of human-derived BIG and a reduced mean hospital stay from 5.5 to 2.5 weeks. BIG is now Food and Drug Administration approved and is available only from the California Department of Health Services (24-h telephone: 510-540-2646). 48, 49 BIG should be administered as early as possible to infants with suspected botulism to interrupt neuromuscular blockade. Equine botulinal antitoxin should not be used for IB and human BIG is not available for use in any form of botulism other than IB.
The prognosis of IB is generally excellent. The main goal is the timely recognition and administration of antitoxin, so as to prevent complications while allowing neuromuscular recovery.
Complications
Secondary infections are common. These include acute otitis media that is related to eustachian tube dysfunction or owing to the presence of nasogastric tube, aspiration pneumonia, hypoxic encephalopathy, hyponatremia owing to excertion of antidiuretic hormone in response to decreased atrial filling because of venous pooling in the paralyzed infant, urinary tract infection owing to indwelling bladder catheter, Clostridium difficile colitis owing to colonic stasis with manifestations of toxic megacolon and necrotizing enterocolitis (56) and septicemia associated with intravascular catheters.
Prevention
As C. botulinum spores are heat resistant and may survive boiling for several hours, home cooking of foods may not destroy C. botulinum spores. Washing and peeling raw foods before cooking may substantially reduce the number of spores, if present.
The single food fed to patients that has been identified as a source of C. botulinum spores, but not of preformed botulinum toxin, is honey. 36, 37, 50 Furthermore, exposure to honey has been implicated as a significant risk factor for type B IB. 50 A survey of honey samples not associated with cases of IB found that 7.5% contained C. botulinum, toxin producing type A or type B or both. The honeys that contained C. botulinum originated in various parts of the USA. 42 As honey is not essential for infant nutrition, it is recommended that it is not fed to infants less than 1 year old. Previously corn syrup contained botulinum spores, but changes in corn syrup production have apparently eliminated this problem.
The full extent of infant morbidity and mortality that result from the intestinal production of botulinum toxin has not been determined. Although an association between infants with botulism and SIDS was suspected, 28 a prospective study failed to confirm the presence of C. botulinum in 248 cases of SIDS. 51 Because the disease may mimic many other disorders, it is possible that more cases of IB may be recognized.
